Clinical utility of folate-containing oral contraceptives

International Journal of Women's Health

Volumn 4, Issue 1, 2012, Pages 185-190

  Lassi, Zohra S ^a   Bhutta, Zulfiqar A ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Contraceptives; Folate; Folate containing oral contraceptives; Oral contraceptives

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DROSPIRENONE PLUS ETHINYLESTRADIOL PLUS MEFOLATE CALCIUM; FOLIC ACID; ORAL CONTRACEPTIVE AGENT; REDUCED FOLATE CARRIER;

BREAST TENDERNESS; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FOLIC ACID BLOOD LEVEL; GENE; GENETIC VARIABILITY; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; MASTALGIA; MENSTRUAL IRREGULARITY; METHYLENE TETRAHYDROFOLATE REDUCTASE GENE; MIGRAINE; MOLECULAR PATHOLOGY; NAUSEA AND VOMITING; NEURAL TUBE DEFECT; NEUROPROTECTION; NEWBORN DEATH; REPRODUCTIVE HEALTH; REVIEW; RISK FACTOR; SOLUTE CARRIER FAMILY 19 FOLATE TRANSPORTER MEMBER 1 GENE; SPOTTING;

EID: 84864090333     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S18611     Document Type: Review

References (59)

1. Kulkarni A, Ehrenkranz RA, Bhandari V. Effect of introduction of synchronized nasal intermittent positive-pressure ventilation in a neonatal intensive care unit on bronchopulmonary dysplasia and growth in preterm infants. Am J Perinatol. 2006;23(4):233-240.
2. Jegatheesan P, Keller RL, Hawgood S. Early variable-flow nasal continuous positive airway pressure in infants ≤ 1000 grams at birth. J Perinatol. 2006;26(3):189-196.
3. World Health Organisation. The global burden of disease: 2004 update. 2008. Available from: http://www.who.int/healthinfo/global_ burden_ disease/GBD_report_2004update_full.pdf. Accessed on December 15, 2011.
4. Ouyang L, Grosse SD, Armour BS, Waitzman NJ. Health care expenditures of children and adults with spina bifida in a privately insured US population. Birth Defects Res A Clin Mol Teratol. 2007;79(7): 552-558.
5. Finan A, Clarke TA, Matthews TG, et al. Strategies for reduction of neonatal mortality. Ir J Med Sci. 1999;168(4):265-267.
6. Wald NJ. Folic acid and the prevention of neural-tube defects. N Engl J Med. 2004;350(2):101-103.
7. van der Linden IJM, Afman LA, Heil SG, Blom HJ. Genetic variation in genes of folate metabolism and neural-tube defect risk. Proc Nutri Soc. 2006;65(02):204-215.
8. Buccimazza SS, Molteno CD, Dunne TT, Viljoen DL. Prevalence of neural tube defects in Cape Town, South Africa. Teratology. 1994; 50(3):194-199.
9. Chatkupt S, Skurnick JH, Jaggi M, Mitruka K, Koenigsberger MR, Johnson WG. Study of genetics, epidemiology, and vitamin usage in familial spina bifida in the United States in the 1990s. Neurology. 1994;44(1):65-65.
10. Milunsky A, Alpert E, Neff RK, Frigoletto FD Jr. Prenatal diagnosis of neural tube defects: IV. Maternal serum alpha-fetoprotein screening. Obstet Gynecol. 1980;55(1):60-66.
11. Hall J, Solehdin F. Folic acid for the prevention of congenital anomalies. Eur J Pediatr. 1998;157(6):445-450.
12. Becerra JE, Khoury MJ, Cordero JF, Erickson JD. Diabetes mellitus during pregnancy and the risks for specific birth defects: a populationbased case-control study. Pediatrics. 1990;85(1):1-9.
13. Lammer EJ, Sever LE, Oakley GP Jr. Valproic acid. Teratology. 1987;35(3):465-473.
14. Edwards MJ, Shiota K, Smith MSR, Walsh DA. Hyperthermia and birth defects. Reprod Toxicol. 1995;9(5):411-425.
15. Graham JM Jr, Edwards MJ. Teratogen update: gestational effects of maternal hyperthermia due to febrile illnesses and resultant patterns of defects in humans. Teratology. 1998;58(5):209-221.
16. Shaw GM, Velie EM, Schaffer D. Risk of neural tube defectaffected pregnancies among obese women. JAMA. 1996;275(14): 1093-1096.
17. Watkins ML, Scanlon KS, Mulinare J, Khoury MJ. Is maternal obesity a risk factor for anencephaly and spina bifida? Epidemiology. 1996;7(5): 507-512.
18. Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. JAMA. 1996;275(14):1089-1092.
19. Brender JD, Felkner M, Suarez L, Canfield MA, Henry JP. Maternal pesticide exposure and neural tube defects in Mexican Americans. Ann Epidemiol. 2010;20(1):16-22.
20. Blatter BM, Roeleveld N, Zielhuis GA, Mullaart RA, Gabreëls FJM. Spina bifida and parental occupation. Epidemiology. 1996;7(2): 188-193.
21. Shaw GM, Nelson V, Olshan AF. Paternal occupational group and risk of offspring with neural tube defects. Paediatr Perinat Epidemiol. 2002;16(4):328-333.
22. Laurence KM, Carter CO, David PA. Major central nervous system malformations in South Wales. II. Pregnancy factors, seasonal variation, and social class effects. Br J Prev Soc Med. 1968;22(4):212-222.
23. Wasserman CR, Shaw GM, Selvin S, Gould JB, Syme SL. Socioeconomic status, neighborhood social conditions, and neural tube defects. Am J Public Health. 1998;88(11):1674-1680.
24. Vrijheid M, Dolk H, Stone D, Abramsky L, Alberman E, Scott JES. Socioeconomic inequalities in risk of congenital anomaly. Arch Dis Child. 2000;82(5):349-352.
25. Elwood JM, Little J, Elwood JH. Epidemiology and Control of Neural Tube Defects. New York, NY: Oxford University Press; 1992.
26. Grewal J, Carmichael SL, Song J, Shaw GM. Neural tube defects: an analysis of neighbourhoodand individual- level socio-economic characteristics. Paediatr Perinatal Epidemiol. 2009;23(2):116-124.
27. Chan A, Robertson EF, Haan EA, Keane RJ, Ranieri E, Carney A. Prevalence of neural tube defects in South Australia, 1966-1991: effectiveness and impact of prenatal diagnosis. Br Med J. 1993;307(6906):703-706.
28. Morris JK, Wald NJ. Prevalence of neural tube defect pregnancies in England and Wales from 1964 to 2004. J Med Screen. 2007;14(2): 55-59.
29. Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80G-. A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab. 2000;70(4): 310-315.
30. van der Put NMJ, Gabreëls F, Stevens E, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Human Genetics. 1998;62(5):1044-1051.
31. Van Beynum IM, Kapusta L, Den Heijer M, et al. Maternal MTHFR 677C. T is a risk factor for congenital heart defects: effect modification by periconceptional folate supplementation. Eur Heart J. 2006;27(8):981-987.
32. Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am J Med Genet C (Semin Med Genet). 2004;125:12-21.
33. Bale J, Stoll B, Lucas A, editors. Reducing Birth Defects: Meeting the Challenge in the Developing World. Washington, DC: The National Academies Press; 2003.
34. Modell B, Kuliev AM. Impact of public health on human genetics. Clin Genet. 1989;36(5):286-298.
35. Alwan A, Modell B. Community Control of Genetic and Congenital Disorders. Alexandria, Egypt: WHO Regional Office for the Eastern Mediterranean; 1997.
36. Ahman E, Zupan J. Neonatal and Perinatal Mortality. Geneva, Switzerland: World Health Organization; 2006.
37. Milunsky A, Canick JA. Maternal serum screening for neural tube and other defects and fetal chromosome abnormalities. West J Med. 1993;159(3):312-317.
38. Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999;55(3):578-592.
39. Pitkin RM. Folate and neural tube defects. Am J Clin Nutr. 2007; 85(1):285S-288S.
40. De Benoist B. Conclusions of a WHO Technical Consultation on folate and vitamin B12 deficiencies. Food Nutr Bull. 2008;29(Suppl 2): S238-S244.
41. Refsum H, Smith AD. Are we ready for mandatory fortification with vitamin B-12? Am J Clin Nutr. 2008;88(2):253-254.
42. Makedos G, Papanicolaou A, Hitoglou A, et al. Homocysteine, folic acid and B12 serum levels in pregnancy complicated with preeclampsia. Arch Gynecol Obstet. 2007;275(2):121-124.
43. Patrick TE, Powers RW, Daftary AR, Ness RB, Roberts JM. Homocysteine and folic acid are inversely related in black women with preeclampsia. Hypertension. 2004;43(6):1279-1282.
44. Tamura T, Picciano MF. Folate and human reproduction. Am J Clin Nutr. 2006;83(5):993-1016.
45. Calonge N, Petitti DB, DeWitt TG, et al. Folic acid for the prevention of neural tube defects: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(9):626-631.
46. Wald N, Sneddon J, Densem J, Frost C, Stone R. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338(8760):131-137.
47. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327(26):1832-1835.
48. Shibuya K, Murray CJL. Low birth weight. In: Murray CJL, Lopez AD, editors. Health Dimensions of Sex and Reproduction. Global Burden of Disease and Injury Series. Cambridge: MA, Harvard University Press; 1998.
49. De-Regil LM, Fernandez-Gaxiola AC, Dowswell T, Pena-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Sys Reviews. 2010; 10:CD007950.
50. Blencowe H, Cousens S, Modell B, Lawn J. Folic acid to reduce neonatal mortality from neural tube disorders. Int J Epidemiol. 2010; 39(Suppl 1):i110-i120.
51. McNulty H, Pentieva K. Folate bioavailability. Proc Nutr Soc. 2004; 63(4):529-536.
52. World Health Organization. Prevention of Neural Tube Defects. Standards for Maternal and Neonatal Care. Geneva, Switzerland: World Health Organization; 2009.
53. Unicef, United Nations, World Health Organization. Iron Deficiency Anaemia: Assessment, Prevention, and Control: A Guide for Programme Managers. Geneva, Switzerland: World Health Organization; 2001.
54. Taylor TN, Farkouh RA, Graham JB, Colligs A, Lindemann M, Lynen R, Candrilli SD. Potential reduction in neural tube defects associated with use of Metafolin-fortified oral contraceptives in the United States. Am J Obstet Gynecol. 2011; 205(5):460.e1-8.
55. Diefenback K, Trummer D, Ebert F, Lissy M, Rohde B, Blode H. Changes in folate levels following cessation of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg coadministration. Eur J Contracept Reprod Health Care. 2010;15(Suppl 1):157-158.
56. FAD Beyaz Highlights of Prescribing Information; 2010. http://www. accessdata.fda.gov/drugsatfda_docs/label/2010/022532s000lbl.pdf. [Accessed on March 22, 2012].
57. Marr J, Sampson-Landers C, Diefenbach K, Trummer D, Bart S, Blode H. Folate and homocysteine levels after 24 weeks administration of YAZ levomefolate calcium 0.451 mg. Eur J Contracept Reprod Health Care. 2010;15(Suppl 1):159.
58. Bart S Sr, Marr J, Diefenbach K, Trummer D, Sampson-Landers C. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, doubleblind, active-controlled, parallel-group, US-based multicenter study. Contraception. 2010;85(1):42-50.
59. Bayer HealthCare Pharmaceuticals. Beyaz prescribing information. 2010. Available from: http://berlex.bayerhealthcare.com/html/products/ pi/fhc/Beyaz_PI.pdf. Accessed February 10, 2012.